✨ Free AI Report
Axsome Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Axsome Therapeutics, Inc.
Company Research

Axsome Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Axsome Therapeutics, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Commercial-stage biotech with diversified CNS portfolio, strong revenue growth, and multiple near-term FDA approval catalysts creating a compelling risk-reward profile. Sales growth is rapid (up 63% and 72% the past two quarters), with analysts looking for 50%-plus gains all of next year. Multiple commercial products and late-stage pipeline catalysts.

What is Axsome Therapeutics, Inc.'s industry? Axsome Therapeutics, Inc. (axsome.com) operates in Biopharmaceutical (CNS Therapeutics). AskCyborg classifies Axsome Therapeutics, Inc. under Biopharmaceutical (CNS Therapeutics) in its company registry.

Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. Unlike many biotechs, it is not a one-dru...

8/ 10Strong

Cyborg Score thesis

Commercial-stage biotech with diversified CNS portfolio, strong revenue growth, and multiple near-term FDA approval catalysts...

Read the full analyst-debate transcript →
Industry Biopharmaceutical (CNS Therapeutics)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Axsome Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Axsome Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Axsome Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Axsome Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Axsome Therapeutics, Inc. Overview

Pro stress-test →

Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. Unlike many biotechs, it is not a one-drug outfit with three products on the market now and more to come. The company demonstrated strong momentum with full year 2025 net product revenue of $638.5 million, representing 66% annual growth.

Strategic Profile

Pro stress-test →

Axsome's stable $800M+ revenue base caps downside and supports ongoing operations, shifting risk from existential to executional and enabling pipeline-driven upside. Auvelity (for major depressive disorder) is the big draw with sales up 69% in Q3, with management thinking peak sales could be $2 billion or so, about four times current run-rate basis. Two drugs are likely to get FDA approval in 2026: AXS-12 targeting narcolepsy ($500 million opportunity) and AXS-05 for Alzheimer's agitation with potential into the $1.5 billion range or more (approval likely in first half of 2026).

Competitive Landscape

Pro stress-test →

Axsome competes in the CNS disorder treatment market with products addressing depression, Alzheimer's disease, narcolepsy, fibromyalgia, and sleep disorders. Key competitors include larger pharmaceutical companies developing similar CNS therapies, though Axsome's differentiated mechanism-of-action portfolio and commercial execution distinguish its positioning in the growing neuroscience market.

Industry Context

Axsome Therapeutics, Inc. operates in Biopharmaceutical (CNS Therapeutics).

Key facts

Founded: 2012 · Headquarters: New York, US · Employees: 683 · Revenue: $638.5M (2025) · Market cap: $37B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Axsome Therapeutics, Inc..

  • Sunosi is showing solid growth for sleep apnea (sales up 35% last quarter) with recent launch of Symbravo for acute migraines.
  • Axsome has another drug in Phase III trials (for ADHD and other indications) that it thinks can be another $1 billion producer.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Axsome initiates FORWARD Phase 3 trial of AXS-14 for fibromyalgia management
  • January 2026FDA accepts priority review of AXS-05 sNDA for Alzheimer's disease agitation
  • +2 moreTrack every material event for Axsome Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Axsome Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CymbaltaDepression and anxiety treatment→LexaproSelective serotonin reuptake inhibitor for depression→ModafinilWakefulness-promoting agent for narcolepsy→LyricaFibromyalgia and neuropathic pain treatment→

Compare Axsome Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Axsome Therapeutics, Inc. operates in Biopharmaceutical (CNS Therapeutics). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical (CNS Therapeutics) research →
NEW · MCP server

Ask your AI assistant about Axsome Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Axsome Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Axsome Therapeutics, Inc. do this quarter?”
“Is Axsome Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Axsome Therapeutics, Inc. do?+
Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. Unlike many biotechs, it is not a one-dru...
What is Axsome Therapeutics, Inc.'s Cyborg Score?+
Axsome Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Axsome Therapeutics, Inc.'s main competitors?+
Named competitors include Cymbalta, Lexapro, Modafinil, Lyrica. The full competitive landscape is in the AskCyborg report.
How can I get the full Axsome Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Axsome Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Axsome Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.